EIF5A2 and colorectal carcinoma: The study had shown that upregulation of eIF5A2 could enhance epithelial mesenchymal transition (EMT) in CRC cells (HCT116 and HT29), and downregulation of eIF5A2 enhanced the chemosensitivity to doxorubicin in eIF5A2-positive cells (75).